title: Reduction of the total immunoglobulin E level by omalizumab in children and adolescents.
authors.forename: Jens-Oliver
authors.initials: JO
authors.lastname: Steiss
authors.forename: Silvia
authors.initials: S
authors.lastname: Rudloff
authors.forename: Hermann
authors.initials: H
authors.lastname: Lindemann
authors.forename: Klaus-Peter
authors.initials: KP
authors.lastname: Zimmer
mesh_terms: D000293:Adolescent; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D000069444:Omalizumab
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E